Avanir Pharmaceuticals has published results from the Phase 3 TARGET study of its AVP-825 intranasal sumatriptan powder compared to placebo for the treatment of migraine. The article appears in the January 2015 issue of Headache. Earlier this year, the company announced positive results from the Phase 3 COMPASS study that compared AVP-825 to oral … [Read more...] about Additional Positive Phase 3 study results for AVP-825 intranasal sumatriptan
Medical
Monaghan Medical presents data showing possible under-dosing from continuous nebulizers
US-based Monaghan Medical, which sells breath actuated nebulizers manufactured by Trudell Medical International (TMI), is presenting data at CHEST 2014 from a study showing that continuous nebulizers may under-dose medication. According to Monaghan changes in a patient's inspiratory/expiratory (I/E) ratio during tidal breathing can result in variable … [Read more...] about Monaghan Medical presents data showing possible under-dosing from continuous nebulizers
Sunovion reports results from dose ranging study of glycopyrrolate inhalation solution
Sunovion Pharmaceuticals has announced that all 4 dose levels of its SUN-101 glycopyrrolate inhalation solution tested in a Phase 2 study produced statistically significant improvements in lung function. The 28-day randomized, double-blind, placebo-controlled study involved more than 280 COPD patients and compared 12.5 mcg, 25 mcg, 50 mcg, and 100 mcg doses of SUN-101 … [Read more...] about Sunovion reports results from dose ranging study of glycopyrrolate inhalation solution
BI study shows Spiriva Handihaler plus Striverdi Respimat superior to Spiriva alone
Data from Boehringer Ingelheims ANHELTO 1 and ANHELTO 2 studies demonstrate that co-administration of the Spiriva HandiHaler tiotropium DPI and the Striverdi Respimat olodaterol SMI produced significantly greater improvement in the lung function of COPD patients than Spiriva alone. The company presented the data at CHEST 2014. The 12-week, double-blind studies … [Read more...] about BI study shows Spiriva Handihaler plus Striverdi Respimat superior to Spiriva alone
Study shows Anoro Ellipta improves lung function better than Spiriva Handihaler
Results from a 24-week study comparing GSK's Anoro Ellipta umeclidinium /vilanterol DPI to Boehringer Ingelheim's Spiriva Handihaler tiotropium DPI published in Respiratory Medicine show statistically greater improvement in trough FEV1 and weighted mean FEV1 0 – 6 hour post dose for UMEC/VI compared to tiotropium. The study involved a total of 905 COPD patients. … [Read more...] about Study shows Anoro Ellipta improves lung function better than Spiriva Handihaler
OrPro announces data from preclinical trial of inhaled thioredoxin
California-based biopharmaceutical company OrPro Therapeutics says that pre-clinical studies of its lead compound, ORP-100, an inhaled thioredoxin, has shown that ORP-100 reduces the viscosity and adhesiveness of the sputum of cystic fibrosis patients both in vitro and in vivo. No inflammation was observed in animals that received "many times the anticipated human … [Read more...] about OrPro announces data from preclinical trial of inhaled thioredoxin
Savara raises $10 million for AeroVanc development
Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis patients, as well as the closing of a $10 million bridge financing round for further development. In December 2013, AeroVanc received … [Read more...] about Savara raises $10 million for AeroVanc development
Verona says RPL554 could treat cystic fibrosis
Verona Pharma says that the company will present data at the upcoming North American Cystic Fibrosis Conference showing that its RPL554 inhaled PDE3/PDE4 inhibitor could be useful in treating CF. According to the company, "The presentation, entitled 'CFTR activation by the dual phosphodiesterase 3/4 inhibitor RPL554 and the MRP4 inhibitor MK571,' reports data … [Read more...] about Verona says RPL554 could treat cystic fibrosis
Monash University to develop inhaled oxytocin in partnership with GSK
Monash University will license technology related to inhaled oxytocin for the treatment of postpartum hemorrhage to to GSK, the university and GSK have announced. Monash and GSK will collaborate on development through early clinical trials, including product optimization and manufacturing process development. Development of the dry powder formulation will be funded … [Read more...] about Monash University to develop inhaled oxytocin in partnership with GSK
Invion announces completion of first feasibility studies for inhaled nadolol
According to Invion, the company has successfully completed the first stage of feasibility studies for its INV102 inhaled nadolol, which it intends to develop for the treatment of asthma, COPD, and cystic fibrosis. Invion is partnered with 3M Drug Delivery Systems for development of INV102 and INV104, inhaled zafirlukast. Nadolol is a beta blocker normally used … [Read more...] about Invion announces completion of first feasibility studies for inhaled nadolol